Months af­ter No­var­tis buy­out, the old Vedere Bio team is back at it with a new pipeline and a fresh $77M

4 years ago
Financing
Startups

Lil­ly and In­novent look to bring their an­ti-PD-1 from Chi­na to the US; Mer­ck KGaA names new EMD Serono pres­i­dent

4 years ago
News Briefing

Sarep­ta touts clean da­ta for com­mer­cial grade Duchenne gene ther­a­py, clear­ing key hur­dle to PhI­II

4 years ago
R&D
Cell/Gene Tx

HHS cracks down on As­traZeneca, Eli Lil­ly, No­var­tis, No­vo Nordisk and Sanofi for lim­it­ing ac­cess to dis­count­ed drugs ...

4 years ago
Pharma
FDA+

An Or­biMed-backed start­up looks to cut ex­cess cor­ti­cos­teroids with mid-stage tests for its lead drug queued up

4 years ago
Financing
Startups

No­vo Nordisk con­tin­ues push­ing be­yond di­a­betes, net­ting PhII win for for­mer Cor­vidia kid­ney pro­gram

4 years ago
R&D

House com­mit­tee un­cov­ers how Hu­mi­ra’s price spiked by 470% as Ab­b­Vie ex­ecs cashed bonus­es tied to the hikes

4 years ago
Pharma
FDA+

Bris­tol My­ers bets big on an­ti-TIG­IT bis­pe­cif­ic from Agenus in a part­ner­ship worth $1.5B+

4 years ago
Deals

Eye­ing clin­i­cal proof-of-con­cept for HER3 drug, Am­gen-part­nered biotech scores $125M for pre­ci­sion an­ti­bod­ies

4 years ago
Financing

Eu­rope's new in­vest­ment firm says it's on a mis­sion to lift up the con­ti­nen­t's 'un­der­ex­ploit­ed' sci­ence

4 years ago
Financing

Jim Wil­son and Tachi Ya­ma­da are at it again — launch­ing a 2nd-gen gene ther­a­py com­pa­ny with an ap­petite for risk, ...

4 years ago
Startups

FDA to Cy­to­Dyn: Those 2 Covid tri­als you keep tout­ing both failed on all end­points and your sub­group analy­sis does­n't ...

4 years ago
Bioregnum
FDA+

SCO­TUS de­clines to re­view En­brel biosim­i­lar case, tee­ing up 30+ years of ex­clu­siv­i­ty and $20B more for Am­gen’s ...

4 years ago
Pharma
FDA+

John­son & John­son do­nates Ebo­la vac­cine amid new out­break; Ji Xing promis­es more than $127M for Mile­stone's nasal ...

4 years ago
News Briefing

Charles Riv­er keeps adding on to its CD­MO arm, snatch­ing up a vi­ral vec­tor play­er for a tidy $350M

4 years ago
Deals
Manufacturing

How to man­u­fac­ture Covid-19 vac­cines with­out the help of J&J, Pfiz­er or Mod­er­na? Bi­ol­yse sees the dif­fi­cul­ties up ...

4 years ago
FDA+
Coronavirus

In­cyte keeps rolling on top­i­cal cream for JAK in­hibitor, pass­ing two PhI­II tests in vi­tili­go

4 years ago
R&D

On the heels of a sting­ing Q1 set­back, Es­pe­ri­on's long­time cham­pi­on is ex­it­ing the helm and turn­ing the wheel over to ...

4 years ago
People

Days ahead of Am­gen split, Cy­to­ki­net­ics reads out post-hoc da­ta sug­gest­ing heart drug works bet­ter in sick­er pa­tients ...

4 years ago
R&D

Patrick Soon-Sh­iong's for­mer chief sci­en­tist takes can­cer com­pa­ny pub­lic in $155M re­verse merg­er

4 years ago
Financing

#ACC21: No­var­tis' En­tresto takes its 2nd fail­ure of the week­end at ACC, show­ing no ben­e­fit in most dire heart fail­ure ...

4 years ago
R&D
Pharma

A T-cell play­er with back­ing from Roche takes next big step for BiTE drugs with 'on-of­f' switch to avoid tox­i­c­i­ty

4 years ago
Financing
Startups

In­sid­er ac­count of Roivan­t's SPAC deal — and that $7.3B val­u­a­tion — re­veals a few se­crets as Matt Gline po­si­tions ...

4 years ago
Financing
Bioregnum

Covid-19 roundup: EU to sup­port vac­cine man­u­fac­tur­ing ef­forts in Africa — re­port; Sput­nik Light ap­proved for use in ...

4 years ago
Coronavirus
First page Previous page 692693694695696697698 Next page Last page
A service from the Financial Times